Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant ...

In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026. On November 7, 2025, Summit ...

Weakened lung function diagnosis can potentially be achieved sooner in the aging process with increased monitoring.

For decades, immune-based cancer therapies have offered hope but also risk, with powerful tumor-fighting effects often ...

Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...

Maida Mangiameli, 75, has defied the odds by surviving over seven years with small-cell lung cancer—a disease with a ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a ...

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, ...